Religare Enterprises gets no objection for Religare Finvest scheme
Religare Enterprises received 'no objection' from NSE and 'no adverse observations' from BSE on July 07, 2026 for its composite scheme of arrangement with Religare Finvest Limited. The exchanges issued directives regarding disclosures of ongoing legal proceedings and financial details. The listing of Religare Finvest shares is subject to SEBI approval and specific conditions, including the submission of an Information Memorandum. The observation letters are valid for six months, and the scheme must be submitted to the NCLT within this period.

*this image is generated using AI for illustrative purposes only.
Religare Enterprises received 'no objection' from the National Stock Exchange of India Limited and 'no adverse observations' from BSE Limited on July 07, 2026 for its composite scheme of arrangement with Religare Finvest Limited. The scheme involves the demerger of Religare Enterprises Limited, acting as the Demerged Company, and Religare Finvest Limited, acting as the Resulting Company, along with their respective shareholders and creditors under sections 230 to 232 of the Companies Act, 2013.
The exchanges issued a set of observations based on comments from the Securities and Exchange Board of India (SEBI). Key directives include disclosing all details of ongoing adjudication, recovery proceedings, and enforcement actions against the company, its promoters, and directors before the Hon'ble NCLT and shareholders. The companies must ensure that all liabilities of the demerged company are transferred to the resulting company and that financials used in the scheme are not older than six months.
Shareholder Disclosures
The companies are required to include comprehensive information in the explanatory statement sent to shareholders. This includes the rationale for the demerger, synergies, cost-benefit analysis, and the basis for the share swap ratio. Specific financial details such as Revenue, PAT, and EBITDA for the last three years, along with the value of assets and liabilities being transferred, must be disclosed. Additionally, the companies must provide details of the Registered Valuer and Merchant Banker issuing the fairness opinion.
Listing Conditions for Religare Finvest Limited
The listing of shares of Religare Finvest Limited pursuant to the scheme is subject to SEBI approval and specific conditions. The company must submit an Information Memorandum containing all details about Religare Finvest Limited and its group companies to the NSE. An advertisement containing this information must be published in newspapers, drawing reference to the memorandum available on the company's website.
The scheme must include provisions ensuring that shares allotted remain frozen in the depository system until listing permission is granted and that there is no change in shareholding pattern or control between the record date and listing. Trading in securities must commence within sixty days of the receipt of the order from the Hon'ble High Court or NCLT.
Regulatory Compliance and Validity
The observation letters are valid for six months from July 07, 2026, within which the scheme must be submitted to the NCLT. The companies must incorporate the observations of SEBI and the stock exchanges in the petition filed before the NCLT. The exchanges clarified that the submission of documents does not imply approval of the financial soundness of the scheme or the correctness of statements made therein. The companies are also required to disclose the no-objection letters on their websites within 24 hours of receipt.
Historical Stock Returns for Religare Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.06% | -2.36% | -7.35% | +7.25% | -5.89% | +53.99% |
How will the requirement to disclose ongoing adjudication and enforcement actions impact shareholder sentiment and voting patterns?
What are the potential market reactions to the share swap ratio once the detailed financials and fairness opinion are disclosed?
Will the six-month validity period for exchange observations pose any risks to the timely approval of the scheme by the NCLT?


































